Phase 1b/2, open label, multicenter, study of intratumoral SD-101 in combination with pembrolizumab in anti-PD1 naive & experienced metastatic melanoma patients

被引：7
|
作者：
Leung, Abraham C. F.
Kummar, Shivaani
Agarwala, Sanjiv S.
Nemunaitis, John J.
Gonzalez, Rene
Drabick, Joseph J.
Schmidt, Emmett V.
Chartash, Elliot
Xing, Biao
Currie, Graeme
Janssen, Robert
Ribas, Antoni
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9550
引用
收藏
页数：5
相关论文
共 50 条
  • [41] AN OPEN-LABEL, MULTICENTER, PHASE 1B STUDY OF DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE AND WITH BACKBONE REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA
    Mateos, M. V.
    Moreau, P.
    Comenzo, R.
    Blade, J.
    Benboubker, L.
    de la Rubia, J.
    Facon, T.
    Fay, J.
    Qin, X.
    Masterson, T.
    Schecter, J.
    Ahmadi, T.
    San-Miguel, J.
    HAEMATOLOGICA, 2015, 100 : 84 - 84
  • [42] IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study.
    Lian, Bin
    Cui, Chuanliang
    Si, Lu
    Sheng, Xinan
    Chi, Zhihong
    Mao, Lili
    Tang, Bixia
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Bai, Xue
    Zhou, Li
    Guo, Jun
    Zhou, Hui
    Xia, Huan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] A MULTICENTER OPEN-LABEL PHASE I/LB STUDY OF SO-C101 AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH SELECTED ADVANCED/METASTATIC SOLID TUMORS
    Marabelle, Aurelien
    Champiat, Stephane
    Garralda, Elena
    Hernando, Alberto
    Janku, Filip
    Raina, Anjali
    Sachse, Richard
    Bechard, David
    Krasnopolskaya, Inna
    Ferrara, Stefano
    LoRusso, Patricia
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A483 - A483
  • [44] OPTIMIZE-1, AN OPEN-LABEL PHASE 1B/2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAZALIMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
    de Coana, Yago Pico
    Smith, Karin Enell
    Falt, Anette
    Flardh, Maria
    Ellmark, Peter
    Cassier, Philippe
    van Laethem, Jean-Luc
    Carlsson, Malin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A567 - A567
  • [45] A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi
    Sureda, Anna
    Araujo, Luis
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Ilidia
    van der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (01) : 108 - 119
  • [46] A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
    Carlo-Stella, Carmelo
    Zinzani, Pier Luigi Luigi
    Sureda, Anna
    Araujo, Luis Francisco
    Casasnovas, Olivier
    Carpio, Cecilia
    Yeh, Su-Peng
    Bouabdallah, Krimo
    Cartron, Guillaume
    Kim, Won Seog
    Cordoba, Raul
    Koh, Youngil
    Re, Alessandro
    Alves, Daniela
    Chamuleau, Martine E. D.
    Le Gouill, Steven
    Lopez-Guillermo, Armando
    Moreira, Maria Ilidia
    Van Der Poel, Marjolein W. M.
    Abbadessa, Giovanni
    Meng, Robin
    Ji, Ran
    Lepine, Lucie
    Saleem, Rao
    Ribrag, Vincent
    BLOOD, 2021, 138
  • [47] Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors
    Rodriguez-Rivera, Ildefonso Ismael
    Moser, Justin C.
    Opyrchal, Mateusz
    Curti, Brendan
    Bilen, Mehmet A.
    Park, Saero
    Bruno, Marissa
    Windt, Paul
    Subramanian, Kulandayan K.
    Chopra, Sameer S.
    Isaacs, Randi
    CANCER RESEARCH, 2023, 83 (08)
  • [48] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Lin, Chia-Chi
    Garralda, Elena
    Schoeffski, Patrick
    Hong, David S.
    Siu, Lillian L.
    Martin, Miguel
    Maur, Michela
    Hui, Rina
    Soo, Ross A.
    Chiu, Joanne
    Zhang, Tian
    Ma, Brigette
    Kyi, Chrisann
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Sarantopoulos, John
    Weickhardt, Andrew
    Carvajal, Richard D.
    Spratlin, Jennifer
    Esaki, Taito
    Rolland, Frederic
    Akerley, Wallace
    Deschler-Baier, Barbara
    Rispoli, Lawrence
    Samant, Tanay S.
    Chowdhury, Niladri Roy
    Gusenleitner, Daniel
    Kwak, Eunice L.
    Askoxylakis, Vasileios
    De Braud, Filippo
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [49] Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
    Jespersen, Henrik
    Bagge, Roger Olofsson
    Ullenhag, Gustav
    Carneiro, Ana
    Helgadottir, Hildur
    Ljuslinder, Ingrid
    Levin, Max
    All-Eriksson, Charlotta
    Andersson, Bengt
    Stierner, Ulrika
    Nilsson, Lisa M.
    Nilsson, Jonas A.
    Ny, Lars
    BMC CANCER, 2019, 19 (1)
  • [50] Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
    Henrik Jespersen
    Roger Olofsson Bagge
    Gustav Ullenhag
    Ana Carneiro
    Hildur Helgadottir
    Ingrid Ljuslinder
    Max Levin
    Charlotta All-Eriksson
    Bengt Andersson
    Ulrika Stierner
    Lisa M. Nilsson
    Jonas A. Nilsson
    Lars Ny
    BMC Cancer, 19
12345